 |
 |
Investor Calendar is powered by PrecisionIR, the leading webcaster of official investor relations events, and offers free access to live and archived corporate communications | |
 |
|
||
|
||||||||
|
|
|
 | |||||||||
 |
December 15, 2009 - 9:30 AM Eastern Lippert/Heilshorn Life Sciences Conference  This podcast has expired.More company presentations from 
Developing proprietary products for the treatment of cancer. Lead programs include ANX-530, a novel emulsion formulation of vinorelbine to treat advanced non-small cell lung cancer and advanced or metastatic breast cancer; and ANX-514, a detergent-free emulsion formulation of docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. Recent news: Raised approximately $9 million in 2Q09 and 3Q09 financings, providing sufficient capital to support operations well into 2010. Plans to submit NDA for ANX-530 by year-end 2009. | ||||||||
 | |||||||||
| Information contained in this webcast is current as of the date and time first presented. The use of pop-up blocking or firewall software may prevent you from accessing this webcast. Please temporarily disable any of these products you may have while attempting to access this event. | |||||||||
|
| ||||||||
 |
|
|
Comments or questions? Click Here Privacy Statement Terms and Conditions ©2000-2013 PrecisionIR. All rights reserved. | |
A part of PrecisionIR Group, www.PrecisionIR.com |
